2. Antibody-drug Conjugate/ADC Related
  3. Antibody-Drug Conjugates (ADCs)
  4. Sofituzumab vedotin

Sofituzumab vedotin  (Synonyms: DMUC5754A)

Cat. No.: HY-P99593 Pureza: 98.97%
COA
SDS
Instrucciones de manejo Technical Support

Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer.

Para uso exclusivo en investigación. No vendemos a pacientes.

Sofituzumab vedotin

Sofituzumab vedotin Estructura química

No. CAS : 1418200-58-4

Tamaño Precio Stock Cantidad
1 mg En stock
5 mg En stock
10 mg En stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 Customer Validation

Sofituzumab vedotin Related Antibodies

Top Publications Citing Use of Products

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1].

In Vitro

Sofituzumab vedotin (DMUC5754A) is an antibody–drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl[2].
Sofituzumab vedotin (3A5-VC-MMAE; 0.1-10000ng/mL; 3 or 5 days) inhibits OVCAR-3 and PC3/MUC16TMlong cells proliferation in a dose-dependent manner[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sofituzumab vedotin Related Antibodies

Cell Proliferation Assay[3]

Cell Line: OVCAR-3 and PC3/MUC16TMlong cells
Concentration: 0.1-10000 ng/mL
Incubation Time: 3 days for OVCAR-3 and 5 days for PC3/MUC16TMlong
Result: Significantly inhibited cell proliferation above 100 ng/mL.
In Vivo

Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) shows potent anti-tumor activity in MUC16-expressing human OVCAR-3 mouse xenograft models[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts[3]
Dosage: 2.8 mg/kg
Administration: IV, once weekly for 4 total doses
Result: Improved survival.
Animal Model: Female CB17 ICR severe combined immunodeficient mice, OVCAR-3 tumors grown in the mammary fat pads[3]
Dosage: 2 mg/kg
Administration: IV, once weekly for 3 total doses
Result: Significantly decreased the tumor volume.
Ensayo clínico
Peso molecular

144000 (average)

No. CAS
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Sofituzumab vedotin]
Envío

Shipping with dry ice.
Almacenamiento

-80°C, protect from light
Pureza y Documentación
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sofituzumab vedotin Related Classifications

  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sofituzumab vedotin1418200-58-4DMUC5754AAntibody-Drug Conjugates (ADCs)Antibody-Drug Conjugatesovarian cancerpancreatic cancerOVCAR-3PC3/MUC16TMlongInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Sofituzumab vedotin
Cat. No.:
HY-P99593
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.